Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hematologic Malignancies

Hematologic Malignancies

Part of Cancer

Subtypes of Hematologic Malignancies

Hematological malignancies 9 Hematological Malignancy 3 Polycythemia Vera 1

21 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hematologic Malignancies

29 trials tracked for Hematologic Malignancies: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 447 citations.

29Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 20 Phase 1 4 Other / NA 3
  1. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 447 cited
  2. Phase 3 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed
  3. Phase 2 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Completed
  4. Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
  5. Phase 2 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Completed
  6. Phase 2 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Completed
Show 23 more trials
  1. Phase 2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Completed
  2. Phase 2 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Completed
  3. Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
  4. Phase 2 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed
  5. Phase 2 A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Completed
  6. Phase 2 A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative Completed
  7. Phase 2 Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support Completed
  8. Phase 2 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation Completed
  9. Phase 2 Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Completed
  10. Phase 2 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed
  11. Phase 2 Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Completed
  12. Phase 2 Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy Completed
  13. Phase 2 Phase II Trial of Pentostatin and Targeted Busulfan Completed
  14. Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
  15. Phase 2 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Completed
  16. Phase 2 Cytokine Induced Killer (CIK) Cells In Leukemia Patients Completed
  17. Phase 1 Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies Completed
  18. Phase 1 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction Completed
  19. Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Completed
  20. Phase 1 A Study Of PF-04449913 In Select Hematologic Malignancies Completed
  21. N/A An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies Completed
  22. N/A Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies Completed
  23. N/A Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hematologic Malignancies: what the trials found

In the management of hematologic malignancies, Denosumab has been shown to significantly improve time to first on-study skeletal related events compared to standard care (p=0.010) 4. Other established interventions include the use of Cyclophosphamide [10, 11], Posaconazole 5, and Pentostatin 17. Specifically, trials involving Pentostatin reported a progression-free survival rate of 55% and an overall survival rate of 68% 17. Additionally, evidence suggests that the addition of photopheresis to Pentostatin for allogeneic stem cell transplantation resulted in a lower incidence of Grade 2-4 acute graft versus host disease (GVHD) compared to no photopheresis 15.

Recent results — preliminary, needs further review

  • • CC-486 was evaluated in a Phase 2 trial 1.
  • • Fludarabine showed favorable outcomes for 6-month probability of survival as assessed by absence of Grade III-IV GVHD or graft failure, with zero cases of acute Grade III-IV GVHD reported 2.
  • • An inpatient serious illness care program was evaluated in a Phase N/A trial 3.
  • • Tildrakizumab was evaluated in a Phase 2 trial 6.

For the clinician treating this condition

  • Denosumab is associated with a statistically significant increase in time to first skeletal related events 4.
  • Pentostatin has been associated with an overall survival rate of 68% and progression-free survival of 55% 17.
  • Photopheresis combined with Pentostatin was associated with lower rates of Grade 2-4 acute GVHD compared to no photopheresis 15.

AI synthesis of 8 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients
Drug Pipeline Sys. Review
Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients Drug exposure varies wildly in patients receiving fludarabine for blood cancers
This review examines fludarabine cellular pharmacology, specifically transport and metabolism, in patients receiving the medication for hema…
Drug exposure varies up to 14.5-fold between patients receiving fludarabine, directly linking low levels to treatment failure and death.
Frontiers May 19, 2026
Narrative review explores Wnt/β-catenin signaling to improve CAR-T cell persistence in hematologic cancers
Infectious Disease Sys. Review
Narrative review explores Wnt/β-catenin signaling to improve CAR-T cell persistence in hematologic cancers Understanding Wnt pathways helps doctors make better CAR-T cell therapies for blood cancer patients
This narrative review synthesizes evidence on Wnt/β-catenin signaling in T cell biology and its potential to enhance CAR-T cell therapy. Act…
Scientists are learning how special cell signals help immune cells last longer in the body. New ideas might make these powerful treatments w…
Frontiers May 18, 2026
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers
Genetics & Precision Medicine Sys. Review
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers New cell therapy upgrade helps immune cells survive longer in tumors
A mini-review explores mitochondrial engineering strategies to boost CAR-T cell efficacy against solid and hematological malignancies, highl…
A new approach to engineering immune cells could solve a major problem: why they stop working inside solid tumors.
Frontiers May 9, 2026
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
Dermatology Sys. Review
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Frontiers Apr 30, 2026
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies
Oncology Sys. Review
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies Adapter-based CAR T cells face hurdles in treating solid tumors and blood cancers
This narrative review examines the potential of adapter-based CAR T cells across multiple cancer types, including solid tumors and hematolog…
A review highlights that making these cells is hard work and they struggle against solid tumors, limiting their current use.
Frontiers Apr 24, 2026
Systematic review of pharmacist-led interventions in hematological malignancies
Drug Pipeline Meta-analysis
Systematic review of pharmacist-led interventions in hematological malignancies Pharmacists Help Blood Cancer Patients Avoid Dangerous Drug Risks
This systematic review of 33 studies examined pharmacist-led interventions for patients with hematological malignancies.
Adding a pharmacist to your care team can make taking complex medicines safer.
Frontiers Apr 24, 2026
Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants
Genetics & Precision Medicine
Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants Hidden Blood Mutations Rewrite Cancer Risk Rules For Millions
This observational analysis of UK Biobank data examined TP53 variants to distinguish germline from somatic clonal expansions and assess asso…
Many scary cancer gene findings in blood tests are not inherited but acquired later in life, changing how doctors assess risk for millions.
medRxiv Apr 16, 2026
Hyperbaric oxygen pretreatment in autologous HSCT patients shows trends toward improved survival and reduced organ damage
Hematology Cohort
Hyperbaric oxygen pretreatment in autologous HSCT patients shows trends toward improved survival and reduced organ damage Pressurized Oxygen Before a Transplant Shows Quiet Promise
This retrospective review examined 19 patients receiving hyperbaric oxygen (HBO) pretreatment versus 225 historical controls undergoing auto…
A pressurized oxygen treatment before transplant may reduce long-term organ damage, though only a couple of endpoints reached statistical si…
Frontiers Apr 13, 2026
Meta-analysis reports 53% 2-year overall survival after haploidentical HSCT in older adults
Hematology Meta-analysis
Meta-analysis reports 53% 2-year overall survival after haploidentical HSCT in older adults Study reviews survival rates for older adults after haploidentical stem cell transplants
A systematic review and meta-analysis of 16 studies including 1,268 adults aged ≥60 years with hematologic malignancies found pooled 2-year …
For older adults with blood cancers, haploidentical stem cell transplants show a two-year survival rate of 53%, though results vary widely b…
Frontiers Apr 2, 2026

Questions about Hematologic Malignancies

Are T cell-based therapies like CAR-T effective for treating hematologic malignancies?

Yes, CAR-T cell therapy is highly effective for hematologic malignancies, with success in blood cancers like ALL, but faces challenges in solid tumors.

Full answer →